Floatz logo

Blinatumomab

Philadelphia Chromosome-Positive

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Philadelphia Chromosome-Positive cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB
Dasatinib
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

precursor B-cell acute lymphoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Precursor B-Cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
70 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →